Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by longondmxon Jan 02, 2007 12:19pm
585 Views
Post# 11942727

One possible reason we have no partner yet

One possible reason we have no partner yetI guess it would make sense that we would not have a partnership announcement until final approval. Afterall, labelling issues, such as for what (knee or all parts of body) and how often to use the product (ie. maximum 3 months, or unlimited) would significantly affect the potential of the product and consequently, the royalties/price a partner would have to pay for the rights to market it. For example, if the FDA's condition was for the product's label to indicate that treatment was for the Knee only for a maximum of 3 months (similar to Canada) the product would be less attractive than if the labelling had other parts of the body listed (ie. all joints, fingers toes, etc.) and no usage limitation. This could be one explanation why Dan has said that he is confident of full approval, as he knows that if he accepts FDA conditions as presented (3 month/knee only labelling), he could have the full approval with no additional issues. Rather than tell the public this, he may have decided to wait in order to ask FDA what it would take to have the product approved for joints, etc... I think we will hear about the issues within the next two weeks - if not this week.
Bullboard Posts